Discover other news

Anima Research Center participates in research on RSV vaccine

Belgium's largest clinical research center encourages further participation in studies to evaluate vaccines

Anima Research Center is currently recruiting participants to participate in a clinical trial for an RSV vaccine from Moderna

Alken, Belgium - Sept. 15, 2022: One of Europe's largest leading clinical research centers, Anima Research Center, based in Alken, Belgium, is calling on the Belgian public to continue its support for clinical studies, especially those focused on vaccines that could potentially combat winter viruses. Anima, which has become one of the most successful clinical research centers in Europe since 2018, wants to ensure that its excellent support for drug and vaccine research continues, especially as winter approaches and seasonal flu and viruses begin to spread.
Viruses that can cause problems in the winter include the "Respiratory Syncytial Virus" or RSV, a highly contagious disease that can cause serious respiratory problems such as pneumonia and even death in the elderly and very young. Every year, more than 160,000 people worldwide die from RSV, and about 7,000 people are diagnosed each year in Belgium alone. There are currently no approved vaccines or treatments for RSV. Anima is collaborating with the U.S. pharmaceutical company Moderna, among others, to evaluate an RSV vaccine under development, aimed at persons over 60 years of age.

Anima Research Center is the largest clinical research center in Belgium. CEO and principal investigator, Dr. Erik Buntinx, founded the center together with his wife, Dr. Hilde Bollen, and his daughter, Linde Buntinx, PhD. Since 2018, Erik and his family, together with a highly experienced team, have built Anima into a leading European site for clinical trials, specializing in studies for central nervous system disorders and vaccines.

Dr. Erik Buntinx , CEO of Anima Research Center and principal investigator, continued: "RSV will present as nothing more than a mild cold in most people, but in the elderly and very young, RSV can even be fatal. There is no vaccine against RSV until now. We are pleased to finally be able to support the pharmaceutical company Moderna in developing a vaccine. I would encourage people to apply if they are eligible - your contribution will help advance research on a vaccine to see if it is effective in preventing RSV."

For more information about the study and to check your eligibility, please visit the Anima Research website:

Subscribe to our quarterly newsletter and stay informed about new studies and developments.